These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 24968976

  • 21. Hemorrhagic pleuropericardial effusion secondary to dabigatran.
    Sanlés González I, de Tapia Majado B, Berrazueta Fernández JR.
    Med Clin (Barc); 2018 Jul 23; 151(2):e7-e8. PubMed ID: 29292107
    [No Abstract] [Full Text] [Related]

  • 22. Prescriber compliance with renal function monitoring in patients taking dabigatran (Pradaxa).
    Thorne K, Dee S, Jayathissa S.
    N Z Med J; 2015 Dec 04; 128(1426):83-8. PubMed ID: 26913911
    [Abstract] [Full Text] [Related]

  • 23. [Safer in everyday clinical care].
    Petersen PF, Grottke O.
    MMW Fortschr Med; 2015 Nov 05; 157(19):79. PubMed ID: 26953417
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L, Chen C, White J.
    Consult Pharm; 2014 Mar 05; 29(3):169-78. PubMed ID: 24589766
    [Abstract] [Full Text] [Related]

  • 26. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.
    Gendron N, Gay J, Lemoine M, Gaussem P, Lillo-Le-Louet A, Smadja DM.
    Haematologica; 2018 May 05; 103(5):e226-e229. PubMed ID: 29472359
    [No Abstract] [Full Text] [Related]

  • 27. Impaired renal function and bleeding in elderly treated with dabigatran.
    Berthelot E, Lavenu-Bombled C, Orostegui-Giron L, Desconclois C, Assayag P.
    Blood Coagul Fibrinolysis; 2014 Sep 05; 25(6):618-20. PubMed ID: 24509332
    [Abstract] [Full Text] [Related]

  • 28. Bleeding risk with dabigatran in the frail elderly.
    Harper P, Young L, Merriman E.
    N Engl J Med; 2012 Mar 01; 366(9):864-6. PubMed ID: 22375994
    [No Abstract] [Full Text] [Related]

  • 29. Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.
    Davis BH, Sangha R, Dillon C, Brown TM, Narayan R, Beasley M, McElderry T, Nolin TD, Limdi NA.
    Am J Kidney Dis; 2021 Jul 01; 78(1):151-153. PubMed ID: 33276038
    [No Abstract] [Full Text] [Related]

  • 30. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators.
    J Am Coll Cardiol; 2014 Feb 04; 63(4):321-8. PubMed ID: 24076487
    [Abstract] [Full Text] [Related]

  • 31. Dabigatran for the prevention and treatment of thromboembolic disorders.
    Enriquez A, Baranchuk A, Redfearn D, Simpson C, Abdollah H, Michael K.
    Expert Rev Cardiovasc Ther; 2015 May 04; 13(5):529-40. PubMed ID: 25843430
    [Abstract] [Full Text] [Related]

  • 32. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
    Chen BC, Sheth NR, Dadzie KA, Smith SW, Nelson LS, Hoffman RS, Winchester JF.
    Am J Kidney Dis; 2013 Sep 04; 62(3):591-4. PubMed ID: 23597859
    [Abstract] [Full Text] [Related]

  • 33. Drug interaction: dabigatran (Pradaxa) and statins.
    Med Lett Drugs Ther; 2017 Jan 30; 59(1513):26. PubMed ID: 28118653
    [No Abstract] [Full Text] [Related]

  • 34. Hemorrhagic complications associated with dabigatran use.
    Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, Hoffman RS, Nelson LS.
    Clin Toxicol (Phila); 2012 Nov 30; 50(9):854-7. PubMed ID: 22970730
    [Abstract] [Full Text] [Related]

  • 35. Dabigatran-dronedarone interaction in a spontaneous reporting system.
    Gandhi PK, Gentry WM, Bottorff MB.
    J Am Pharm Assoc (2003); 2013 Nov 30; 53(4):414-9. PubMed ID: 23892815
    [Abstract] [Full Text] [Related]

  • 36. The use of dabigatran in elderly patients.
    Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D.
    Arch Intern Med; 2011 Jul 25; 171(14):1285-6. PubMed ID: 21788545
    [Abstract] [Full Text] [Related]

  • 37. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
    Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, Eris JM, Tran H, Patel JP, Roberts DM.
    Clin Toxicol (Phila); 2015 Mar 25; 53(3):156-63. PubMed ID: 25661675
    [Abstract] [Full Text] [Related]

  • 38. Enhanced elimination of dabigatran through extracorporeal methods.
    Awad NI, Brunetti L, Juurlink DN.
    J Med Toxicol; 2015 Mar 25; 11(1):85-95. PubMed ID: 25448250
    [Abstract] [Full Text] [Related]

  • 39. The options of reversal of a dabigatran effect.
    Srivali N, Thongprayoon C, Ungprasert P.
    Am J Emerg Med; 2015 Dec 25; 33(12):1836-7. PubMed ID: 26422190
    [No Abstract] [Full Text] [Related]

  • 40. The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation.
    Pahs L, Beavers C, Schuler P.
    Crit Pathw Cardiol; 2015 Jun 25; 14(2):53-61. PubMed ID: 26102014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.